Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. The company's primary product includes Tyzeka/Sebivo for the treatment of hepatitis B virus. It also develops IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for the treatment of human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS). In addition, Idenix Pharmaceuticals, Inc. focuses on the development of drugs for the treatment of hepatitis C virus. It has a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize its NNRTI compounds, including IDX899 for the treatment of HIV/AIDS. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Idenix Pharmaceuticals, Inc. is a subsidiary of Novartis Pharma AG.

Merck was founded in 1668 as a pharmacy and is the oldest pharmaceutical business in the world. The Merck family owns about 70% of the company. Merck is leaving its mark on the global pharmaceutical market. Through a network of nearly 200 companies in over 60 countries, the Merck develops, makes, and sells pharmaceutical and chemical products for global consumption. Name-brand prescription drugs include treatments for cardiovascular disease, cancers, infertility, and neurological disorders; the company also makes over-the-counter pharmaceuticals. Aside from drugs, the firm makes specialty chemicals, including laboratory reagents and cosmetic ingredients, as well as liquid crystals for televisions.

Xanodyne Pharmaceuticals, Inc. company develops and manufactures drugs for pain management and women's health. Its commercial offerings include pain treatments Darvocet, Roxicodone, and Oramorph SR, as well as Duet prenatal vitamins. Zipsor, a treatment for mild to moderate inflammatory pain such as arthritic pain, and Lysteda, a treatment for menorrhagia (excessive menstrual bleeding), were both approved by the FDA in 2009. Xanodyne has several other drugs in development, including one for mild to moderate pain in late-stage clinical trials. The company funds its development efforts through sales of its commercial products, which are marketed through an internal sales force.

ChemOvation offers contract drug discovery research and design services to pharmaceutical and biotechnology companies. ChemOvation has expertise in organic and medicinal chemistry, and drug discovery. ChemOvation also provides protein binding and compound solubility measurements for clients' metabolism research. ChemOvation's team of contractors is built around a core of organic chemists and technicians. Formed in 1999, the company merged with KuDOS Pharmaceuticals in 2000. ChemOvation dissolved those bonds in 2005 having spun off from KuDOS and is independent once again.

Quest PharmaTech aims to shed some light on dermatology and cancer treatments. Working with Hypocrellin, a photosensitive compound isolated from pigments found in fungi on bamboo, the company has developed its SonoLight Technology. The compound is relatively harmless until activated by light or ultrasound, whereupon it begins to destroy tissue. The company's pipeline of drug candidates include treatments to facilitate laser hair removal, address acne, and improve prostate cancer therapies. The company has sold off several earlier products to focus on its current pipeline and continues to consider strategic alternatives to facilitate its growth.

Glycotex wants to see such creatures as ulcers, bed sores, and sunburns put on the Australian endangered species list. The biopharmaceutical company researches and develops products based on molecular glucan receptors that trigger the healing process. Connective tissue repair, skin ulcers, and bone fractures are primary recovery fields for its glucan receptor products. Glycotex's lead product candidate, MG3601, is a topical treatment for ulcers, and it has completed Phase II clinical trials. Other therapeutic candidates include Glucocol and Glucoprime, active ingredients designed to treat tendon regeneration and topical needs, respectively. Its parent company, Novogen, owns 84% of Glycotex.

Celgene Signal Research (also known as Celgene Research San Diego) wouldn't want it any other way. This Celgene division works to identify potential drug candidates with a focus on regulating genes and the production of disease-causing proteins. Much of its work has been to identify and map certain kinase and ligase proteins, which future Celgene drugs are then designed to inhibit. Celgene Signal Research's drug discovery programs target inflammatory diseases, as well as cancers such as leukemia.

Warner Chilcott plc company was founded in 1968 and is headquartered in Rockaway, New Jersey. Warner Chilcott PLC, formerly Warner Chilcott Limited, is a Bermuda-based specialty pharmaceutical company focused on the women’s healthcare and dermatology segments of the United States pharmaceutical market. It is an integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. Its operations are carried through its wholly-owned subsidiaries in the United States, Puerto Rico, the Republic of Ireland and Northern Ireland. The Companies franchises are comprised of complementary portfolios of established branded and development-stage products. In October 2009, the Company announced it completed the acquisition of The Procter & Gamble Company’s global branded prescription pharmaceutical business.

Entelos using its PhysioLab technology, the company develops computer models of diseases that drug makers and other researchers can use to design drugs and other therapies more effectively. The disease models integrate known genomic and proteomic data with physiologic, environmental, and other information collected from clinical trials, case studies, and other sources. Entelos has developed PhysioLab models for asthma, diabetes, obesity, and rheumatoid arthritis. The models are built in partnership with such firms as Eli Lilly, PDL Biopharma, and UCB Pharma.

Idera Pharmaceuticals, Inc. company was founded in 1989 and is based in Cambridge, Massachusetts. Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. The company designs and creates proprietary Toll-Like Receptors (TLR) to modulate immune responses, including TLR agonist, a compound that stimulates an immune response through the targeted TLR; and TLR antagonist, a compound that blocks activation of an immune response through the targeted TLR. Its drug candidates include IMO-2125, a TLR9 agonist, which is in Phase 1 clinical trial for hepatitis C virus infection; and TLR7, 8, and 9 agonists that are in research stage for viral diseases. The company also develops IMO-3100, a dual TLR7/TLR9 antagonist, which is in preclinical development stage for autoimmune and inflammatory diseases, such as lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis.In addition, its drug candidates also comprise TLR7 and TLR8 agonists that are in research stage for solid tumor cancers. The company has a licensing and collaboration agreement with Merck KGaA to research, develop, and commercialize TLR9 agonists for the treatment of cancer, excluding cancer vaccines; a license and research collaboration agreement with Merck & Co., Inc. to research, develop, and commercialize therapeutic and prophylactic vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer's disease; and a research collaboration and option agreement, and a license, development, and commercialization agreement with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.